{
    "clinical_study": {
        "@rank": "1595", 
        "arm_group": {
            "arm_group_label": "TH-302  plus  Nab-paclitaxel plus Gemcitabine", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety,\n      tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine\n      and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or\n      metastatic pancreatic adenocarcinoma."
        }, 
        "brief_title": "Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects greater than or equal to (>=) 18 years of age with locally advanced\n             unresectable or metastatic pancreatic adenocarcinoma proven by histology or cytology\n             and previously untreated with chemotherapy or systemic therapy other than:\n\n               -  Radiosensitizing doses of 5-fluorouracil;\n\n               -  Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months\n                  after completion of gemcitabine;\n\n               -  Neoadjuvant chemotherapy if relapse occurred at least 6 months after surgical\n                  resection;\n\n               -  Adjuvant chemotherapy if relapse occurred at least 6 months after completion of\n                  adjuvant chemotherapy\n\n          -  Subjects may have measurable or non-measurable disease according to RECIST 1.1.\n\n          -  Eastern cooperative oncology group (ECOG) performance status of 0 or 1\n\n          -  Acceptable hematological status, liver and renal function as defined in the protocol\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Significant cardiac or peripheral vascular arterial disease\n\n          -  Known brain, leptomeningeal or epidural metastases (unless treated and well\n             controlled for at least 3 months)\n\n          -  Severe chronic obstructive or other pulmonary disease with hypoxemia\n\n          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic\n             therapy\n\n          -  Subjects receiving concomitant treatment with radiotherapy or other investigational\n             drugs\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047500", 
            "org_study_id": "EMR200592-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "TH-302  plus  Nab-paclitaxel plus Gemcitabine", 
                "description": "TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.", 
                "intervention_name": "TH-302", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TH-302  plus  Nab-paclitaxel plus Gemcitabine", 
                "description": "Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m^2  as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.", 
                "intervention_name": "Nab-paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TH-302  plus  Nab-paclitaxel plus Gemcitabine", 
                "description": "Gemcitabine will be administered at a dose ranging from 800-1000 mg/m^2  as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "TH-302", 
            "Nab-paclitaxel", 
            "Gemcitabine"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Clinical Trials Office - All Mayo Clinic Locations", 
                    "phone": "507-538-7623"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259-5499"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects experiencing dose limiting toxicity (DLT)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 28 of Cycle 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047500"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression free survival (PFS) time", 
                "safety_issue": "No", 
                "time_frame": "Time from enrollment to progressive disease (PD) or occurrence of death due to any cause within 120 days of either first administration of study drug or the last tumor assessment"
            }, 
            {
                "measure": "Percentage of subjects with objective response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) criteria", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks from Day 1 of Cycle 1 until disease progression or  within 1 week after discontinuation of study treatment"
            }, 
            {
                "measure": "Duration of overall response according to RECIST version 1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks from Day 1 of Cycle 1 until disease progression or  within 1 week after discontinuation of study treatment"
            }, 
            {
                "measure": "Percentage of subjects with disease control according to RECIST version 1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks from Day 1 of Cycle 1 until disease progression or  within 1 week after discontinuation of study treatment"
            }, 
            {
                "measure": "Tumor metabolic response assessed by positron emission tomography (PET) scans according to European Organization for Research and Treatment of Cancer (EORTC) criteria", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 8 weeks after Day 1 of Cycle 1"
            }, 
            {
                "measure": "Number of subjects with Treatment-emergent adverse events (TEAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 30 after the last dose of study treatment"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "collaborator": {
                "agency": "Threshold Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}